Form 6-K GW PHARMACEUTICALS PLC For: Dec 22

�

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

�

�

Form 6-K

�

�

�

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

�

For the Month of December, 2014

�

Commission File Number: 001-35892

�

�

�

GW PHARMACEUTICALS�PLC

(Translation of registrant’s name into English)

�

�

�

Porton Down Science Park, Salisbury

Wiltshire, SP4�0JQ

United Kingdom

(Address of principal executive offices)

�

�

�

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

�

Form 20-F��x

�

Form 40-F���

�

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

�

Yes���

�

No���

�

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

�

Yes���

�

No���

�

�

�

�

Other Events

�

On December 22, 2014, GW Pharmaceuticals plc (Nasdaq: GWPH) issued a press release announcing that it has been selected for addition to the NASDAQ Biotechnology Index^� (Nasdaq:NBI), which will become effective at the open of U.S. markets today. The press release is attached as Exhibit 99.1 and is incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

�

�

Exhibits

�

99.1

Press release dated December 22, 2014

�

�

��

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

�

�	GW Pharmaceuticals plc
�	�	�
�	By:	/s/ Adam George
�	Name:	Adam George
�	Title:	Chief Financial Officer
�	�	�
Date: December 22, 2014	�	�

�

Exhibit 99.1

�

�

GW Pharmaceuticals Added to NASDAQ Biotechnology Index

�

London, UK, 22 December 2014: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that it has been selected for addition to the NASDAQ Biotechnology Index^� (Nasdaq:NBI), which will become effective at the open of U.S. markets today.

�

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index(SM) Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the NASDAQ Biotechnology Index and the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

�

About GW Pharmaceuticals plc

�

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex�, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex�, which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome.GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

�

�

�

Forward-looking statements

�

This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the relevance of GW products commercially available and in development, the clinical benefits of Sativex� and Epidiolex� and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

�

Enquiries:

�

GW Pharmaceuticals plc	(Today)��+44 20 3727 1000
Justin Gover, Chief Executive Officer	(Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations (U.S.)	+1 917 280 2424 / +1 401 500 6570
�	�
FTI Consulting (Media Enquiries)	�
Ben Atwell / Simon Conway / John Dineen (UK)	+ 44 20 3727 1000
Robert Stanislaro (U.S.)	+1 212 850 5657
�	�
Trout Group, LLC (U.S. investor relations)	�
Todd James / Chad Rubin	+1 646 378 2900
�	�

�

�

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Largest Chinese Trade Delegation in Years Secures Cooperative Intentions in New Zealand
• Transaction in Own Shares
• Huhtamaki to consolidate its production footprint by closing a site in Malaysia